



Möln dal 2021-04-01

## Center of Rehabilitation, UMCG Groningen, the Netherlands, introduces the OPRA™ Implant System and Targeted Muscle Reinnervation (TMR).

Located approximately 200 kilometers from the nation's capital, The University Medical Center Groningen ([UMCG](#)) is one of the largest hospitals in the Netherlands, and is the largest employer in the Northern Netherlands.

UMCG focuses on advanced care, education, training, and research; and not only provides patient-centric care, but also aims to conduct revolutionary scientific and educational research on treating the healthy aged population. This in order to build the future of healthcare, and a healthy and active population.

Committed to these values, the UMCG is one of the pioneering medical centers which has introduced the [OPRA™ Implant System](#) in the treatment of both upper and lower extremity amputees. The Center of Rehabilitation being able to offer osseointegration treatment combined with TMR, provides a “state of the art” treatment option for amputees in the Netherlands.

The efficient and highly skilled team is led by Professor and Department Chair of Orthopedics, Dr. P. C. Jutte, and is comprised of plastic surgeon Dr. T.R. Middelberg, Dr. A. H. Vrieling, department of Rehabilitation Medicine, Professor Dr. J.H.B. Geertzen, specializing in lower extremity amputation, and Professor Dr. C.K. van der Sluis, who specializes in upper extremity rehabilitation.

Says Professor Jutte, “we’re driven to enhance the ability of our amputee patients to the max so they’re able to fully participate in society; the introduction of OPRA and TMR will benefit them tremendously”

Maria Lopez, CEO at Integrum, shared the following “we are both extremely pleased and proud of the collaboration with UMCG Groningen, a leading medical center which offers evidence based, cutting edge treatment to all of its patients”.

### **For further information, please contact:**

Maria Lopez, CEO

Cell. +46 (0) 708-46 10 69

Email: [maria.lopez@integrum.se](mailto:maria.lopez@integrum.se)

Certified Adviser:  
Erik Penser Bank AB  
Tel. +46 (0) 8 463 8000  
Email: certifiedadviser@penser.se

Integrum AB is a publicly-traded company (INTEG B: Nasdaq First North exchange) based outside of Gothenburg, Sweden, with a US subsidiary in San Francisco, CA. Since 1990, osseointegration, the science behind the OPRA™ Implant System has been helping individuals with amputations towards an improved quality of life.

Thorough surgical experience gained over almost three decades, from 500 surgeries in 14 countries, has led to the development of Integrum's system for bone-anchored prosthetics –a beneficial alternative to the traditionally used socket prosthesis. Integrum's OPRA™ Implant System was first approved by the US Food and Drug Administration (FDA) in 2015 for use in the US under a Humanitarian Use Device (HUD) designation, which was reviewed through the Humanitarian Device Exemption (HDE) pathway, which limited the level of marketing and sales activities.

In December 2020, Integrum successfully completed the most stringent medical device regulatory procedure in the world, and based on the solid scientific data submitted, was granted a PMA by the FDA for the OPRA™ Implant System, which is the only technology approved for above-knee, bone-anchored prosthetics in the U.S. More information on the company and its innovative solutions for amputees can be found at [www.integrum.se](http://www.integrum.se)